Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 1,738 trials

Mild Age-Related Hearing Loss: DX243 Treatment

We are testing a new treatment for people with mild age-related hearing loss to see if it is safe and effective. The study starts with healthy volunteers before moving to patients.

Age-Related Hearing Loss>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineOtolaryngology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

B-cell Non-Hodgkin Lymphoma: Surovatamig Treatment Study

We are studying how well surovatamig works and its safety for adults with certain types of blood cancers. This trial aims to learn more about its effects on lymphoma and patient experiences.

Relapsed or Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Diabetic Retinopathy: COLIRIOBCN070660 Eye Drops

We are studying a new eye drop treatment for people with moderately severe to severe diabetic retinopathy. The goal is to see if it can reduce eye damage and improve vision.

Diabetic Retinopathy1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesEndocrinologyOphthalmology

Acute Myeloid Leukemia: MB-dNPM-1-TCR.1 Treatment

We are studying a new therapy for patients with relapsed or refractory acute myeloid leukemia. The goal is to understand its safety and how well it works compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

B-Cell Acute Lymphoblastic Leukemia: AZD0486 Study

We are investigating whether AZD0486 is safe and effective for adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This trial aims to understand how well it works compared to existing treatments.

B-Cell Acute Lymphoblastic LeukaemiaSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

HIV Treatment: Doravirine/Tenofovir/Lamivudine Study

We are studying a combination of medications for people living with HIV who have a history of specific mutations. The goal is to see if this treatment helps maintain viral control and improves health over time.

HIV Disease1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

Acute Myeloid Leukemia≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Lung Cancer: Enhanced Skin Care Management

We are studying if improved skin care can help reduce skin side effects in patients with advanced EGFR-mutated lung cancer receiving amivantamab and lazertinib. This trial compares enhanced care to standard skin management.

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteDermatologyOncology

Pancreatic Cancer: FOLFIRINOX3 Treatment

We are testing a chemotherapy combination for patients with advanced pancreatic cancer who cannot undergo surgery. The goal is to see if it is safe and effective as a first treatment option.

Advanced Pancreatic Cancer>2 yearsEfficacy phase (II)Oncology

Metastatic Castration-Resistant Prostate Cancer: Gedatolisib and Darolutamide Study

We are studying a new combination of gedatolisib and darolutamide for men with metastatic castration-resistant prostate cancer. The trial will evaluate safety, tolerability, and how well this treatment works.

Castration-Resistant Prostate Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Sepsis-Associated Acute Kidney Injury: TIN816 Treatment Study

We are investigating a new treatment, TIN816, for individuals with sepsis-related kidney injury. The study aims to see if it improves kidney function and overall health compared to a placebo.

Sepsis-Related Acute Kidney Injury≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Acute Myeloid Leukemia: RVU120 with Venetoclax

We are studying a new treatment combining RVU120 and Venetoclax for patients with acute myeloid leukemia who did not respond to earlier therapies. The goal is to assess its safety and effectiveness in improving their condition.

Acute Myeloid Leukemia6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Sinonasal Carcinoma: Pembrolizumab and Chemotherapy

We are studying the safety and effectiveness of combining pembrolizumab with chemotherapy for patients with locally advanced sinonasal carcinoma. This trial aims to explore new treatment options for better outcomes.

Locally Advanced Sinonasal Carcinoma1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

Advanced Breast Cancer: Patritumab Deruxtecan Study

We are testing a new drug for patients with advanced breast cancer to see how well it works. The study will also analyze biomarkers to understand treatment responses better.

Advanced Breast CancerEfficacy phase (II)Oncology

Non-Small Cell Lung Cancer: DS-1062a Treatment Study

We are testing a new antibody-drug conjugate for patients with advanced non-small cell lung cancer. The study aims to see how effective it is and how individual responses may vary.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Oncology

Advanced Breast Cancer: HER3-DXd Treatment Study

We are investigating a new drug for patients with inoperable advanced breast cancer who have progressed after previous treatment. The study aims to understand its safety and effectiveness, both alone and in combination with other therapies.

HER2-positive and HER2-low Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology